The U.S. Pentagon is rolling out new clinical guidelines that require mandatory testosterone deficiency screening for male service members aged 30 and older. Reporting from multiple outlets says the policy includes blood testing, while treatment options are addressed through defined clinical pathways.
The guidance follows Defense Secretary Pete Hegseth’s announcement in July, and one outlet reports it becomes effective immediately and applies to both active-duty and reserve personnel. The Pentagon frames the effort as aimed at identifying and managing potential hormonal and energy-availability issues that could affect readiness. For men under 30, testing is described as not routine unless requested or triggered by clinical warning signs. One outlet also says the guidance covers women differently, focusing on symptoms such as fatigue and menstrual cycle disruption rather than routine testosterone blood tests.
Outlets also differ in emphasis and raise cautions. One report notes the guidance includes situations where off-label testosterone might be prescribed in women for specific cases, and it highlights expert concerns that broad screening could lead to unnecessary or potentially harmful treatment. It also says the FDA plans an expert meeting in mid-September to discuss testosterone’s medical use.
